$12.40
0.90% today
Nasdaq, Oct 28, 05:18 pm CET
ISIN
CA05156V1022
Symbol
AUPH

Aurinia Pharmaceuticals Inc. Stock price

$12.29
+1.23 11.12% 1M
+4.29 53.63% 6M
+3.31 36.86% YTD
+5.05 69.75% 1Y
+4.38 55.37% 3Y
-3.76 23.43% 5Y
+9.29 309.67% 10Y
-72.71 85.54% 20Y
Nasdaq, Closing price Mon, Oct 27 2025
+0.40 3.36%
ISIN
CA05156V1022
Symbol
AUPH
Industry

Key metrics

Basic
Market capitalization
$1.6b
Enterprise Value
$1.4b
Net debt
positive
Cash
$315.1m
Shares outstanding
132.7m
Valuation (TTM | estimate)
P/E
28.6 | 18.6
P/S
6.2 | 5.9
EV/Sales
5.3 | 5.0
EV/FCF
14.9
P/B
4.8
Financial Health
Equity Ratio
68.6%
Return on Equity
1.5%
ROCE
16.3%
ROIC
38.5%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$260.1m | $275.9m
EBITDA
$88.5m | $108.4m
EBIT
$69.0m | $92.5m
Net Income
$60.6m | $87.7m
Free Cash Flow
$92.4m
Growth (TTM | estimate)
Revenue
25.6% | 17.3%
EBITDA
369.3% | 186.4%
EBIT
230.3% | 401.9%
Net Income
220.4% | 1,425.7%
Free Cash Flow
5,260.9%
Margin (TTM | estimate)
Gross
89.5%
EBITDA
34.0% | 39.3%
EBIT
26.5%
Net
23.3% | 31.8%
Free Cash Flow
35.5%
More
EPS
$0.4
FCF per Share
$0.7
Short interest
7.0%
Employees
130
Rev per Employee
$1.8m
Show more

Is Aurinia Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,039 stocks worldwide.

Aurinia Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:

Buy
85%
Hold
15%

Financial data from Aurinia Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
260 260
26% 26%
100%
- Direct Costs 27 27
5% 5%
10%
233 233
31% 31%
90%
- Selling and Administrative Expenses 126 126
34% 34%
48%
- Research and Development Expense 24 24
27% 27%
9%
88 88
369% 369%
34%
- Depreciation and Amortization 19 19
3% 3%
7%
EBIT (Operating Income) EBIT 69 69
230% 230%
27%
Net Profit 61 61
220% 220%
23%

In millions USD.

Don't miss a Thing! We will send you all news about Aurinia Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aurinia Pharmaceuticals Inc. Stock News

Positive
Seeking Alpha
6 days ago
Aurinia Pharmaceuticals is rated BUY, driven by strong Lupkynis sales growth and a robust cash position supporting pipeline development. AUPH's Lupkynis leads as the first FDA-approved oral therapy for lupus nephritis, with 22% YoY revenue growth and expanding physician adoption. The company's pipeline drug, AUR200, targets dual immune proteins and offers long-term diversification potential in ...
Neutral
Business Wire
13 days ago
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at ACR Convergence and ASN Kidney Week 2025.
Neutral
Business Wire
29 days ago
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Responds to Now Retracted LinkedIn Post.
More Aurinia Pharmaceuticals Inc. News

Company Profile

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Head office Canada
CEO Peter Greenleaf
Employees 130
Founded 1993
Website www.auriniapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today